ロード中...
Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis
Hepatocellular carcinoma (HCC), the third major cause of cancer mortality, can result from non-alcoholic steatohepatitis (NASH). Due to limited efficacy of drugs approved for HCC and no drug available yet for NASH, identification of new effective treatments is crucial. Here, we investigated whether...
保存先:
| 出版年: | Front Pharmacol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6775500/ https://ncbi.nlm.nih.gov/pubmed/31611801 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.01129 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|